作者
Katharina Kusejko, Álvaro Auñón, Bernhard Jost, Benito Natividad, Carol Strahm, Christine Thurnheer, Daniel Pablo-Marcos, Dorsaf Slama, Giulia Scanferla, Ilker Uckay, Isabelle Waldmann, Jaime Esteban, Jaime Lora-Tamayo, Martin Clauss, Marta Fernandez-Sampedro, Marjan Wouthuyzen-Bakker, Matteo Carlo Ferrari, Natalie Gassmann, Parham Sendi, Philipp Jent, Philippe C Morand, Prakhar Vijayvargiya, Rihard Trebše, Robin Patel, Roger D Kouyos, Stéphane Corvec, Tobias Siegfried Kramer, Vincent A Stadelmann, Yvonne Achermann
发表日期
2021/6/15
期刊
Clinical infectious diseases
卷号
72
期号
12
页码范围
e1064-e1073
出版商
Oxford University Press
简介
Background
Cutibacterium species are common pathogens in periprosthetic joint infections (PJI). These infections are often treated with β-lactams or clindamycin as monotherapy, or in combination with rifampin. Clinical evidence supporting the value of adding rifampin for treatment of Cutibacterium PJI is lacking.
Methods
In this multicenter retrospective study, we evaluated patients with Cutibacterium PJI and a minimal follow-up of 12 months. The primary endpoint was clinical success, defined by the absence of infection relapse or new infection. We used Fisher’s exact tests and Cox proportional hazards models to analyze the effect of rifampin and other factors on clinical success after PJI.
Results
We included 187 patients (72.2% male, median age 67 years) with a median follow-up of 36 months. The surgical intervention was a 2-stage exchange in …
学术搜索中的文章
K Kusejko, Á Auñón, B Jost, B Natividad, C Strahm… - Clinical infectious diseases, 2021